Assessing cardiovascular and kidney health using metabolomics in patients with heart disease
Official title: Cardiovascular-Renal Adverse oUtcome rIsk aSsessment systEm for Coronary Heart Disease Complicated With Chronic Kidney Disease Based on Targeted Lipid METabolomics
Run by China-Japan Friendship Hospital · NCT06383208 · Data updated 2026-11-12
This study is testing if certain fat-related substances in the blood can help predict health outcomes for adults with both heart disease and kidney problems.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 470 (estimated) |
| Sponsor | China-Japan Friendship Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | April 1, 2024 |
| Main results expected | March 31, 2027 |
| Study ends | March 31, 2027 |
| Registry record updated | April 25, 2024 |
| Trial ID | NCT06383208 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18-80 diagnosed with coronary heart disease and chronic kidney disease.
✕Probably not a fit
Patients with severe psychiatric illnesses, end-stage renal disease, or those who have undergone kidney transplantation may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate the relationship between lipid metabolites and the prognosis of patients suffering from both coronary heart disease (CHD) and chronic kidney disease (CKD). By analyzing specific lipid metabolites that are elevated in patients with reduced kidney function, the study seeks to identify potential biomarkers that could indicate adverse outcomes. The research focuses on patients aged 18-80 who have been diagnosed with CHD and have clarified renal function status. The findings could provide insights into the cardiovascular-kidney-metabolic syndrome and improve risk assessment for these patients.
Why it matters
Potential benefit: If successful, this study could lead to improved prognostic assessments and targeted interventions for patients with both coronary heart disease and chronic kidney disease.
How similar studies have gone: While the approach of using lipid metabolomics is emerging, similar studies have shown promise in identifying biomarkers for cardiovascular and renal diseases.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age 18-80 years old; 2. Diagnosed with CHD during hospitalization through coronary angiography, including ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation acute coronary syndrome (NST-ACS), stable angina pectoris; 3. Patients with clarified renal function status.; CKD is defined as meeting one of the following criteria, with a duration of more than 3 months: eGFR \< 60 ml/min/1.73 m² or eGFR ≥ 60 ml/min/1.73 m² and urinary albumin-to-creatinine ratio (uACR) ≥ 30 mg/g; Exclusion Criteria: 1. Pregnancy or lactation; 2. Severe valve disease or severe mechanical complications requiring surgical intervention; 3. Severe psychiatric illness or other reasons that impede follow-up compliance; 4. Severe hematologic disorders or end-stage malignant tumors; 5. Having undergone kidney transplantation or long-term maintenance dialysis; 6. Severe liver disease (Child-Pugh class C); 7. Received acute renal failure dialysis treatment within 12 weeks prior to screening for enrollment; 8. Severe chronic lung disease requiring long-term mechanical ventilation support or awaiting lung transplantation; 9. Life expectancy less than 1 year.
Where it's running
-
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Principal investigator: Zheng Jingang, MD — China-Japan Friendship Hospital
- Study coordinator: Chen Qiang
- Email: dawangchen@163.com
- Phone: +86 13882712184
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Research on health inequality and genetic disparity in cardiovascular diseases
This study is trying to understand how health differences and genetics affect heart diseases in people from various ethnic backgrounds in the UK to help improve treatments for everyone.
-
Assessing the impact of comorbidities on postoperative complications.
This study looks at how having other health issues affects the chances of complications after abdominal surgery to help doctors better understand and manage risks for their patients.
-
Clinical decision support to help consider SGLT2 inhibitors after AKI in type 2 diabetes
This pilot test checks if a CDS message given to clinicians can help decide whether to consider SGLT2 inhibitors for adults with type 2 diabetes who recently had acute kidney injury.
-
NMR-based Risk Test and Digital Health Support for midlife adults in Eloisa
This study tests whether an NMR metabolomics risk test can guide tailored digital health programs for midlife adults at risk of diabetes, heart disease, stroke, kidney disease, or fatty liver.
-
Screening for lipid disorders in children and teens with chronic diseases to flag cardiovascular risk
This study tests a blood test and a questionnaire to screen children and teens with chronic conditions for lipid metabolism disorders and familial hyperlipidemia.
-
Prospective cardiac surgery cohort to improve perioperative care
A multi-center study will test a large, forward-looking database of adults undergoing heart surgery to better understand what affects short- and long-term outcomes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.